LQDA Earnings

LQDA reported its earnings on 2026-03-05, showcasing a revenue of 92.02M against an estimate of 66.99M, resulting in a 37.37% surprise. The EPS was 0.15, surpassing the expected 0.08 by 87.5%. The stock experienced a 0.41% price change on the earnings day and a 12.94% change over the next five days, reflecting market reactions to the results.

Following LQDA's earnings announcement on 2026-03-05, the stock price moved by 0.41% on the day of the release. Over the subsequent five days, it saw a 12.94% change. Historically, LQDA's stock price tends to shift by an average of -3.28% in the 10 days leading up to earnings and 2.16% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate LQDA's annual revenue to reach 79.84M, while the EPS is projected at 0.38. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between LQDA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, LQDA's stock price typically moves by -3.28% in the 10 days before its earnings and 2.16% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.38 and revenue of 79.84M.

The earnings call summary indicates strong financial performance and optimistic future guidance. YUTREPIA's market share increased significantly, and management is confident in achieving a $1 billion revenue target by 2027. Product differentiation and strategic clinical trials are expected to drive growth. Despite some vague responses, the overall sentiment is positive, with no major concerns raised. The lack of market cap data prevents a more nuanced prediction, but the positive outlook suggests a stock price increase in the short term.